C-07 Sanofi-NCI Neurotoxicity Gr 1. P/D that do not interfere with function Gr 2. P/D interfering with function, but not ADL Gr 3. P/D with pain or interference with ADL Gr 4. Persistent PD that are disabling or life-threatening
Conclusions The addition of oxaliplatin to weekly bolus FULV significantly improves 3-year DFS in patients with Stage II and III colon cancer The data confirm and extend the results of the Mosaic trial
Conclusions The benefit of oxaliplatin does not appear to be dependent on the schedule of FULV administration The data support the use of weekly bolus FULV in combination with oxaliplatin in adjuvant colon cancer
Your consent to our cookies if you continue to use this website.